Navigation Links
Hepatitis C responds best to combo of ribavirin and interferon, study concludes

bility to kill virus cells and inhibiting the ability of viruses to make new copies of themselves and proliferate.

Ribavirin belongs to a class of drugs called nucleoside analogues, which includes some anti-HIV drugs such as AZT (zidovudine). Ribavirin used alone does not have any effect on HCV but in combination with interferon it appears to boost the immune system and help slow virus replication.

The researchers were measuring failure to respond adequately to treatment under each course of treatment.

In tests for presence of the virus among those who had never been treated for the disease, 83 percent of those on interferon did not respond after six months, compared to 58 percent of those getting interferon plus ribavarin.

Among those who had relapsed after previous treatment 87 percent of interferon-only patients did not respond, compared to 51 percent who were on combination therapy.

Of the patients who had not responded at all to previous therapy, 95 percent of the interferon patients did not respond, compared to 81 percent of those getting both drugs.

Other measures reported by the researchers included patient status at the end of treatment, quality of life and whether patients had a reduction in liver inflammation. Patients who had combination therapy did better in all categories. Side effects, however, were much more common in the combination therapy across all groups than in the interferon-alone group.

The most frequent side effect was anemia, which occurred in 22 percent of cases of combination recipients and less than 1 percent of the interferon group. Other side effects that occurred much more frequently in the combination therapy patients included a reduced number of white blood cells; skin disorders such as dry skin and rash; stomach complaints such as lack of appetite, nausea and indigestion; infections; insomnia; difficulty breathing, cough and fatigue.

"The beneficial effect of adding ri
'"/>

Source:Center for the Advancement of Health


Page: 1 2 3

Related biology news :

1. Scientists Replicate Hepatitis C Virus in Laboratory
2. Norovirus, AIDS vaccine and Hepatitis Virus
3. UCLA study assesses cost-effectiveness of Hepatitis B drugs
4. Natural Killers Could Lead to New Hepatitis Treatments
5. FDA Approves New Treatment for Chronic Hepatitis B
6. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
7. Use of high hydrostatic pressure to inactivate Hepatitis A virus in oysters studied
8. Hepatitis C complicated by morphine withdrawal
9. Hepatitis B accounts for 40 percent of missing Asian women
10. Hepatitis C therapy: Inhibiting newly discovered microDNA molecule
11. Hepatitis E takes a piggyback
Post Your Comments:
(Date:7/11/2014)... cannabinoid receptor type 1 can inhibit voltage-gated ... reduce neurotransmitter release. However, some scholars demonstrated ... extracellular Ca2+ influx and increase neurotransmitter release. ... Hospital Affiliated to Tongji Medical College, Huazhong ... whole cell voltage-clamp and calcium imaging in ...
(Date:7/11/2014)... brains of all vertebrates, information is transmitted through ... chemical signal to be passed from one brain ... most abundant type of synapse, can be either ... learning, memory, perception and cognition, and the balance ... function. For instance, every time we learn ...
(Date:7/10/2014)... 2014  Pomerantz LLP has filed a class ... the "Company")(NYSE-MKT: PVCT) and certain of its officers.  ... Court, Middle District of Tennessee ... class consisting of all persons or entities who ... 17, 2013 and May 22, 2014, both dates ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... newly identified human bocavirus was found in nearly 5 ... very young children. Researchers from the Centers for ... the International Conference on Emerging Infectious Diseases , "Our ... with pneumonia in Thailand, especially among young children," says ...
... by the National Institute of Allergy and Infectious Diseases ... have identified a defect in the immune response of ... them at risk of developing serious complications following smallpox ... the National Jewish Medical and Research Center in Denver, ...
... experts who attended a national avian flu conference last fall ... able to manufacture and stockpile enough vaccine or antiviral medication ... into a form that can be spread easily from human ... Carnegie Mellon University. The results of the survey will be ...
Cached Biology News:Bocavirus infection may be associated with pneumonia in Thailand, especially in children 2Defective immune system response to smallpox vaccine detailed in new study 2Defective immune system response to smallpox vaccine detailed in new study 3Medical experts: US unlikely to have enough vaccines to stop avian flu 2
(Date:7/10/2014)... even geckos and spiders can sit upside down forever. Nanophysics ... demonstrated this in an article just published in Physical ... benefit. , Geckos and spiders that seem to be able ... fascinated researchers worldwide for many years. We will soon be ... way as the gecko,s foot. But the fact is, sooner ...
(Date:7/10/2014)... researchers at the University of Illinois at Urbana-Champaign ... the interplay of spin and heat at the ... spintronic devices for data storage and information processing. ... as spin-angular momentum. In a typical charge current, ... spin current," explained David Cahill, a professor of ...
(Date:1/15/2014)... Using an approach akin to assembling a club ... and Technology (NIST) researchers have succeeded in crafting ... the flammability of foam commonly used in upholstered ... of the nanotube-coated polyurethane foam was reduced 35 ...
(Date:1/15/2014)... , Jan. 15, 2014  Bill Jacobs Automotive, a group ... is teaming up with the Heartland Blood Center and offering ... drive. The drive takes place Saturday, Jan. 18 at the ... 2 p.m. (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  ...
Breaking Biology Technology:Even geckos can lose their grip 2University of Illinois study advances limits for ultrafast nano-devices 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2Join the Bill Jacobs Auto blood drive and receive a free oil change 2
... its recent analysis of the elastic nonwovens market, Frost & ... Frost & Sullivan Technology Leadership of the Year Award for ... styrenic block copolymers (SBCs). Already established as an innovator in ... of SBCs, the MD6705, G1643, and MD6717 grades are in ...
... Inc. (Nasdaq: CRTX ), a specialty pharmaceutical ... primarily for the respiratory market, today announced that Craig ... presenting a corporate overview at BioCentury,s 16th Annual Future ... EDT on Thursday, April 2, 2009, at the Millennium ...
... important provisional patent applicationsTAMPA, Fla., March 31 ... in cancer immunotherapy, has recently filed two provisional ... immunotherapy. The company,s research is focused on the ... specifically, iLRP - immature Laminin Receptor Protein, as ...
Cached Biology Technology:Frost & Sullivan Recognizes Kraton Polymers for Developing a New Generation of Polymer Grades Suitable for High-Speed Processing in Nonwoven Manufacture 2Frost & Sullivan Recognizes Kraton Polymers for Developing a New Generation of Polymer Grades Suitable for High-Speed Processing in Nonwoven Manufacture 3Frost & Sullivan Recognizes Kraton Polymers for Developing a New Generation of Polymer Grades Suitable for High-Speed Processing in Nonwoven Manufacture 4Frost & Sullivan Recognizes Kraton Polymers for Developing a New Generation of Polymer Grades Suitable for High-Speed Processing in Nonwoven Manufacture 5Cornerstone Therapeutics to Present at BioCentury's 2009 Future Leaders in the Biotech Industry Conference 2Immunotherapy-Based Provisional Patents Mark Significant Discovery 2Immunotherapy-Based Provisional Patents Mark Significant Discovery 3
Mouse monoclonal [RL13] to LAP1 ( Abpromise for all tested applications). SwissProtID: Q96NW7...
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Biology Products: